Bionano Genomics Stock Analysis

Bionano Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.55. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bionano Genomics recorded a loss per share of 2.3. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 7th of August 2023. Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 299 people. For more info on Bionano Genomics please contact Robert MBA at 858 888 7600 or go to https://www.bionano.com.

Bionano Genomics Investment Alerts

Bionano Genomics Upcoming and Recent Events

Bionano Largest EPS Surprises

View All Earnings Estimates

Bionano Stock Institutional Investors

Note, although Bionano Genomics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bionano Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 27.04 M.

Bionano Profitablity

Management Efficiency

Bionano Genomics has return on total asset (ROA) of (0.3264) % which means that it has lost $0.3264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3833) %, meaning that it created substantial loss on money invested by shareholders. Bionano Genomics' management efficiency ratios could be used to measure how well Bionano Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of January 2025, Return On Tangible Assets is likely to drop to -1.22. In addition to that, Return On Capital Employed is likely to drop to -1.78. At this time, Bionano Genomics' Net Tangible Assets are very stable compared to the past year. As of the 19th of January 2025, Non Currrent Assets Other is likely to grow to about 9 M, while Total Assets are likely to drop about 142.9 M.

Technical Drivers

As of the 19th of January, Bionano Genomics shows the Risk Adjusted Performance of (0.06), standard deviation of 8.07, and Mean Deviation of 5.13. Bionano Genomics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Bionano Genomics Price Movement Analysis

Bionano Genomics Insider Trading Activities

Bionano Genomics Outstanding Bonds

Bionano Genomics Predictive Daily Indicators

Bionano Genomics Forecast Models

Bionano Genomics' time-series forecasting models are one of many Bionano Genomics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bionano Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bionano Genomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bionano shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bionano Genomics. By using and applying Bionano Stock analysis, traders can create a robust methodology for identifying Bionano entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bionano analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bionano analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Bionano Genomics stock analysis indicators help investors evaluate how Bionano Genomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bionano Genomics shares will generate the highest return on investment. By understating and applying Bionano Genomics stock analysis, traders can identify Bionano Genomics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.